Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review

K.S. Samarina, Yuliana Yurevna Assesorova, I.V. Berger,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-2-162-171

The use of tyrosine kinase inhibitors (TKIs) dramatically improved long-term survival rates in chronic myeloid leukemia (CML) patients. Despite high specificity for BCR::ABL1 tyrosine kinase, TKIs can induce adverse events including increased risk of cardiovascular complications. One of the cardiovascular risk factors is an elevated homocysteine (HC) level. However, neither homocysteine status nor hyperhomocysteinemia effect on the disease course in CML patients on TKI therapy have been sufficiently studied. This paper aims to comprehensively analyze the current literature data on HC level changes and HC metabolism factors in CML patients. The review is based on the articles indexed in the PubMed, MEDLINE and other databases dealing with the mechanisms of HC metabolism genesis, transformation, and causes for its dysfunction in CML patients prior to and on therapy with TKIs of different generations. Despite the limited number of studies, a literature analysis suggests that HC level is a helpful marker of the folate cycle status, metabolic status, endothelial function, and tumor cell growth activity in CML patients.

  1. Al Mutairi F. Hyperhomocysteinemia: Clinical Insights. J Cent Nerv Syst Dis. 2020;12:1179573520962230. doi: 10.1177/1179573520962230. DOI: https://doi.org/10.1177/1179573520962230
  2. Васильев А.Г., Морозова К.В., Брус Т.В. и др. Роль нарушений обмена гомоцистеина в патологических процессах. Российские биомедицинские исследования. 2022;7(1):44–59. doi: 10.56871/1453.2022.70.70.007. [Vasiliev A.G., Morozova K.V., Brus T.V., et al. The role of homocystein metabolic disorders in pathological processes. Rossiiskie biomeditsinskie issledovaniya. 2022;7(1):44–59. doi: 10.56871/1453.2022.70.70.007. (In Russ)] DOI: https://doi.org/10.56871/1453.2022.70.70.007
  3. Yuan D, Chu J, Lin H, et al. Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis. Front Cardiovasc Med. 2023;9:1109445. doi: 10.3389/fcvm.2022.1109445. DOI: https://doi.org/10.3389/fcvm.2022.1109445
  4. Koklesova L, Mazurakova A, Samec M, et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J. 2021;12(4):477–505. doi: 10.1007/s13167-021-00263-0. DOI: https://doi.org/10.1007/s13167-021-00263-0
  5. Das D, Das T, Pramanik S. Hyperhomocysteinemia presenting as exclusive small vessel coronary artery disease (CAD) in a young. J Family Med Prim Care. 2022;11(6):3298–301. doi: 10.4103/jfmpc.jfmpc_1539_21. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1539_21
  6. Kaplan P, Tatarkova Z, Sivonova MK, et al. Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems. Int J Mol Sci. 2020;21(20):7698. doi: 10.3390/ijms21207698. DOI: https://doi.org/10.3390/ijms21207698
  7. Marroncini G, Martinelli S, Menchetti S, et al. Hyperhomocysteinemia and Disease-Is 10 μmol/L a Suitable New Threshold Limit? Int J Mol Sci. 2024;25(22):12295. doi: 10.3390/ijms252212295. DOI: https://doi.org/10.3390/ijms252212295
  8. Fossard G, Blond E, Balsat M, et al. Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients. Haematologica. 2016;101(3):e86–е90. doi: 10.3324/haematol.2015.135103. DOI: https://doi.org/10.3324/haematol.2015.135103
  9. Jin N, Huang L, Hong J, et al. Elevated homocysteine levels in patients with heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(33):e26875. doi: 10.1097/MD.0000000000026875. DOI: https://doi.org/10.1097/MD.0000000000026875
  10. Hasan T, Arora R, Bansal AK, et al. Disturbed homocysteine metabolism is associated with cancer. Exp Mol Med. 2019;51(2):1–13. doi: 10.1038/s12276-019-0216-4. DOI: https://doi.org/10.1038/s12276-019-0216-4
  11. Haguet H, Douxfils J, Mullier F, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16(1):5–12. doi: 10.1080/14740338.2017.1261824. DOI: https://doi.org/10.1080/14740338.2017.1261824
  12. Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3(6):851–61. doi: 10.1182/bloodadvances.2018025874. DOI: https://doi.org/10.1182/bloodadvances.2018025874
  13. Haguet H, Bouvy C, Delvigne AS, et al. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated with Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020;11:1007. doi: 10.3389/fphar.2020.01007. DOI: https://doi.org/10.3389/fphar.2020.01007
  14. Vlasveld LT, Bos GM, Ermens AA, et al. Hyperhomocysteinemia and functional cobalamin deficiency due to granulocytosis-induced alterations in the cobalamin-binding protein. Haematologica. 2006;91(3):394–6.
  15. Caocci G, Mulas O, Capodanno I, et al. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Ann Hematol. 2021;100(8):2005–14. doi: 10.1007/s00277-020-04392-w. DOI: https://doi.org/10.1007/s00277-020-04392-w
  16. Sicuranza A, Ferrigno I, Abruzzese E, et al. Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Front Oncol. 2022;12:835563. doi: 10.3389/fonc.2022.835563. DOI: https://doi.org/10.3389/fonc.2022.835563
  17. Ларина Т.Н., Супрун С.В. Фолатный цикл: патогенетические механизмы осложнений беременности (литературный обзор). Бюллетень физиологии и патологии дыхания. 2018;1(70):113–20. doi: 10.12737/article_5c127a27ba9a85.88292840. [Larina T.N., Suprun S.V. Folate cycle: pathogenetic mechanisms of pregnancy complications (review). Bulletin physiology and pathology of respiration. 2018;1(70):113–20. doi: 10.12737/article_5c127a27ba9a85.88292840. (In Russ)] DOI: https://doi.org/10.12737/article_5c127a27ba9a85.88292840
  18. Sbodio JI, Snyder SH, Paul BD. Regulators of the transsulfuration pathway. Br J Pharmacol. 2019;176(4):583–93. doi: 10.1111/bph.14446. DOI: https://doi.org/10.1111/bph.14446
  19. Gregory JF, DeRatt BN, Rios-Avila L, et al. Vitamin B6 nutritional status and cellular availability of pyridoxal 5’-phosphate govern the function of the transsulfuration pathway’s canonical reactions and hydrogen sulfide production via side reactions. Biochimie. 2016;126:21–6. doi: 10.1016/j.biochi.2015.12.020. DOI: https://doi.org/10.1016/j.biochi.2015.12.020
  20. Pajares MÁ. Posttranslational Regulation of Mammalian Sulfur Amino Acid Metabolism. Int J Mol Sci. 2025;26(6):2488. doi: 10.3390/ijms26062488. DOI: https://doi.org/10.3390/ijms26062488
  21. Škovierová H, Vidomanová E, Mahmood S, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17(10):1733. doi: 10.3390/ijms17101733. DOI: https://doi.org/10.3390/ijms17101733
  22. Fu Y, Wang X, Kong W. Hyperhomocysteinaemia and vascular injury: Advances in mechanisms and drug targets. Br J Pharmacol. 2018;175(8):1173–89. doi: 10.1111/bph.13988. DOI: https://doi.org/10.1111/bph.13988
  23. Blacher J, Benetos A, Kirzin JM, et al. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol. 2002;90(6):591–5. doi: 10.1016/s0002-9149(02)02561-4. DOI: https://doi.org/10.1016/S0002-9149(02)02561-4
  24. Kolling J, Scherer EB, Da Cunha AA, et al. Homocysteine induces oxidative–nitrative stress in heart of rats: Prevention by folic acid. Cardiovasc Toxicol. 2011;11(1):67–73. doi: 10.1007/s12012-010-9094-7. DOI: https://doi.org/10.1007/s12012-010-9094-7
  25. Petras M, Tatarkova Z, Kovalska M, et al. Hyperhomocysteinemia as a risk factor for the neuronal system disorders. J Physiol Pharmacol. 2014;65(1):15–23.
  26. Esse R, Barroso M, De Almeida IT, Castro R. The contribution of homocysteine metabolism disruption to endothelial dysfunction: state-of-the-art. Int J Mol Sci. 2019;20(4):867. doi: 10.3390/ijms20040867. DOI: https://doi.org/10.3390/ijms20040867
  27. Ostrakhovitch EA, Tabibzadeh S. Homocysteine and age-associated disorders. Aging Res Rev. 2019;49:144–64. doi: 10.1016/j.arr.2018.10.010. DOI: https://doi.org/10.1016/j.arr.2018.10.010
  28. Perła-Kaján J, Jakubowski H. Dysregulation of epigenetic mechanisms of gene expression in the pathologies of hyperhomocysteinemia. Int J Mol Sci. 2019;20(13):3140. doi: 10.3390/ijms20133140. DOI: https://doi.org/10.3390/ijms20133140
  29. Zhu Y, Shen J, Cheng Q, et al. Plasma homocysteine level is a risk factor for osteoporotic fractures in elderly patients. Clin Interv Aging. 2016;11:1117–21. doi: 10.2147/CIA.S107868. DOI: https://doi.org/10.2147/CIA.S107868
  30. Farina N, Jernerén F, Turner C, et al. Homocysteine concentrations in the cognitive progression of Alzheimer’s disease. Exp Gerontol. 2017;99:146–50. doi: 10.1016/j.exger.2017.10.008. DOI: https://doi.org/10.1016/j.exger.2017.10.008
  31. Dong B, Wu R. Plasma homocysteine, folate and vitamin B12 levels in Parkinson’s disease in China: A meta-analysis. Clin Neurol Neurosurg. 2020;188:105587. doi: 10.1016/j.clineuro.2019.105587. DOI: https://doi.org/10.1016/j.clineuro.2019.105587
  32. Peker E, Demir N, Tuncer O, et al. The levels of vitamın B12, folate and homocysteine in mothers and their babies with neural tube defects. J Matern Fetal Neonatal Med. 2016;29(18):2944–8. doi: 10.3109/14767058.2015.1109620. DOI: https://doi.org/10.3109/14767058.2015.1109620
  33. Hannibal L, Lysne V, Bjørke-Monsen AL, et al. Biomarkers and Algorithms for the Diagnosis of Vitamin B12 Deficiency. Front Mol Biosci. 2016;3:27. doi: 10.3389/fmolb.2016.00027. DOI: https://doi.org/10.3389/fmolb.2016.00027
  34. Zou J, Shu M, Chen J, et al. Associations of Serum Homocysteine with Bone Mineral Density and Osteoporosis Incidence in Chinese Middle-Aged and Older Adults: A Retrospective Cohort Study. Nutrients. 2025;17(1):192. doi: 10.3390/nu17010192. DOI: https://doi.org/10.3390/nu17010192
  35. Xu W, Cheng Y, Zhu H. Evaluation of an Association of Blood Homocysteine Levels with Gastric Cancer Risk From 27 Case-Control Studies. Medicine (Baltimore). 2016;95(20):e3700. doi: 10.1097/MD.0000000000003700. DOI: https://doi.org/10.1097/MD.0000000000003700
  36. Liu Z, Cui C, Wang X, et al. Plasma Levels of Homocysteine and the Occurrence and Progression of Rectal Cancer. Med Sci Monit. 2018;24:1776–83. doi: 10.12659/MSM.909217. DOI: https://doi.org/10.12659/MSM.909217
  37. Morris AA, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40(1):49–74. doi: 10.1007/s10545-016-9979-0. DOI: https://doi.org/10.1007/s10545-016-9979-0
  38. Majtan T, Kožich V, Kruger WD. Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria. Br J Pharmacol. 2023;180(3):264–78. doi: 10.1111/bph.15991. DOI: https://doi.org/10.1111/bph.15991
  39. Kripps KA, Sremba L, Larson AA, et al. Methionine synthase deficiency: Variable clinical presentation and benefit of early diagnosis and treatment. J Inherit Metab Dis. 2022;45(2):157–68. doi: 10.1002/jimd.12448. DOI: https://doi.org/10.1002/jimd.12448
  40. Ruiz-Mercado M, Vargas MT, de Soto IP, et al. Methionine synthase reductase deficiency (CblE): A report of two patients and a novel mutation. Hematology. 2016;21(3):193–7. doi: 10.1179/1607845415Y.0000000017. DOI: https://doi.org/10.1179/1607845415Y.0000000017
  41. Kose E, Besci O, Gudeloglu E, et al. Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature. J Pediatr Endocrinol Metab. 2020;33(11):1487–99. doi: 10.1515/jpem-2020-0096. DOI: https://doi.org/10.1515/jpem-2020-0096
  42. Ni J, Zhang L, Zhou T, et al. Association between the MTHFR C677T polymorphism, blood folate and vitamin B12 deficiency, and elevated serum total homocysteine in healthy individuals in Yunnan Province, China. J Chin Med Assoc. 2017;80(3):147–53. doi: 10.1016/j.jcma.2016.07.005. DOI: https://doi.org/10.1016/j.jcma.2016.07.005
  43. Li Y, Qiu S, Shi J, et al. Association between MTHFR C677T/A1298C and susceptibility to autism spectrum disorders: a meta-analysis. BMC Pediatr. 2020;20(1):449. doi: 10.1186/s12887-020-02330-3. DOI: https://doi.org/10.1186/s12887-020-02330-3
  44. Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks. Nutrients. 2021;13(12):4562. doi: 10.3390/nu13124562. DOI: https://doi.org/10.3390/nu13124562
  45. Zarembska E, Ślusarczyk K, Wrzosek M. The Implication of a Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Homocysteine Metabolism and Related Civilisation Diseases. Int J Mol Sci. 2023;25(1):193. doi: 10.3390/ijms25010193. DOI: https://doi.org/10.3390/ijms25010193
  46. Dai C, Fei Y, Li J, et al. A Novel Review of Homocysteine and Pregnancy Complications. Biomed Res Int. 2021;2021:6652231. doi: 10.1155/2021/6652231. DOI: https://doi.org/10.1155/2021/6652231
  47. Загубная О.А., Нарциссов Я.Р. Молекулярные механизмы, лежащие в основе терапевтического действия витамина В6. Фармация и фармакология. 2022;10(6):500–14. doi: 10.19163/2307-9266-2022-10-6-500-514. [Zagubnaya O.A., Nartsissov Y.R. Molecular mechanisms underlying therapeutic action of vitamin B6. Pharmacy & Pharmacology. 2022;10(6):500–14. doi: 10.19163/2307-9266-2022-10-6-500-514. (In Russ)] DOI: https://doi.org/10.19163/2307-9266-2022-10-6-500-514
  48. Kaldygulova L, Ukybassova T, Aimagambetova G, et al. Biological Role of Folic Acid in Pregnancy and Possible Therapeutic Application for the Prevention of Preeclampsia. Biomedicines. 2023;11(2):272. doi: 10.3390/biomedicines11020272. DOI: https://doi.org/10.3390/biomedicines11020272
  49. Mucha P, Kus F, Cysewski D, et al. Vitamin B12 Metabolism: A Network of Multi-Protein Mediated Processes. Int J Mol Sci. 2024;25(15):8021. doi: 10.3390/ijms25158021. DOI: https://doi.org/10.3390/ijms25158021
  50. Prasad K. Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment. Int J Angiol. 2024;33(4):262–70. doi: 10.1055/s-0044-1788280. DOI: https://doi.org/10.1055/s-0044-1788280
  51. Perna AF, Sepe I, Lanza D, et al. Hyperhomocysteinemia in chronic renal failure: alternative therapeutic strategies. J Ren Nutr. 2012;22(1):191–4. doi: 10.1053/j.jrn.2011.10.008. DOI: https://doi.org/10.1053/j.jrn.2011.10.008
  52. Zaric BL, Obradovic M, Bajic V, et al. Homocysteine and Hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948–61. doi: 10.2174/0929867325666180313105949. DOI: https://doi.org/10.2174/0929867325666180313105949
  53. Aleksic D, Djokic D, Golubicic I, et al. The importance of the blood levels of homocysteine, folic acid and vitamin B12 in children with malignant diseases. J BUON. 2013;18(4):1019–25.
  54. Majumder A. Targeting Homocysteine and Hydrogen Sulfide Balance as Future Therapeutics in Cancer Treatment. Antioxidants (Basel). 2023;12(8):1520. doi: 10.3390/antiox12081520. DOI: https://doi.org/10.3390/antiox12081520
  55. Mohamed R, Sharma I, Ibrahim AS, et al. Hyperhomocysteinemia Alters Retinal Endothelial Cells Barrier Function and Angiogenic Potential via Activation of Oxidative Stress. Sci Rep. 2017;7(1):11952. doi: 10.1038/s41598-017-09731-y. DOI: https://doi.org/10.1038/s41598-017-09731-y
  56. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med. 2005;5(2):124–39. doi: 10.1055/s-2005-872398. DOI: https://doi.org/10.1055/s-2005-872398
  57. Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res. 2018;41(4):372–83. doi: 10.1007/s12272-018-1016-4. DOI: https://doi.org/10.1007/s12272-018-1016-4
  58. Calcaterra V, Larizza D, De Giuseppe R, et al. Diet and Lifestyle Role in Homocysteine Metabolism in Turner Syndrome. Med Princ Pract. 2019;28(1):48–55. doi: 10.1159/000494138. DOI: https://doi.org/10.1159/000494138
  59. Harats D, Yodfat O, Doolman R, et al. Homocysteine elevation with fibrates: is it a class effect? Isr Med Assoc J. 2001;3(4):243–6.
  60. Ljungblad UW, Lindberg M, Eklund EA, et al. Nitrous oxide in labour predicted newborn screening total homocysteine and is a potential risk factor for infant vitamin B12 deficiency. Acta Paediatr. 2022;111(12):2315–21. doi: 10.1111/apa.16530. DOI: https://doi.org/10.1111/apa.16530
  61. Caris MG, Kuipers RS, Kiestra BE, et al. Nitrous oxide abuse leading to extreme homocysteine levels and thrombosis in young adults: a case series. J Thromb Haemost. 2023;21(2):276–83. doi: 10.1016/j.jtha.2022.10.002. DOI: https://doi.org/10.1016/j.jtha.2022.10.002
  62. Al Hageh C, Alefishat E, Ghassibe-Sabbagh M, et al. Homocysteine levels, H-Hypertension, and the MTHFR C677T genotypes: A complex interaction. Heliyon. 2023;9(6):e16444. doi: 10.1016/j.heliyon.2023.e16444. DOI: https://doi.org/10.1016/j.heliyon.2023.e16444
  63. Malinowska J, Kolodziejczyk J, Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim Pol. 2012;59(2):185–94. doi: 10.18388/abp.2012_2137. DOI: https://doi.org/10.18388/abp.2012_2137
  64. Shimizu Y, Fujiu K. Homocysteine as a Key Player in Lifestyle Management of Arrhythmia. Int Heart J. 2020;61(4):631–2. doi: 10.1536/ihj.20-327. DOI: https://doi.org/10.1536/ihj.20-327
  65. Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, et al. Vitamin B12, folate, and homocysteine in metabolic syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1221259. doi: 10.3389/fendo.2023.1221259. DOI: https://doi.org/10.3389/fendo.2023.1221259
  66. Saija C, Currò M, Ientile R, et al. Impact of Alterations in Homocysteine, Asymmetric Dimethylarginine and Vitamins-Related Pathways in Some Neurodegenerative Diseases: A Narrative Review. Int J Mol Sci. 2025;26(8):3672. doi: 10.3390/ijms26083672. DOI: https://doi.org/10.3390/ijms26083672
  67. Lai WK, Kan MY. Homocysteine-Induced Endothelial Dysfunction. Ann Nutr Metab. 2015;67(1):1–12. doi: 10.1159/000437098. DOI: https://doi.org/10.1159/000437098
  68. Zhang DD, Cao Y, Mu JY, et al. Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study. Stroke Vasc Neurol. 2022;7(4):302–9. doi: 10.1136/svn-2021-001102. DOI: https://doi.org/10.1136/svn-2021-001102
  69. Wang X, Wang Y, Zhang L, et al. L-Cystathionine Protects against Homocysteine-Induced Mitochondria-Dependent Apoptosis of Vascular Endothelial Cells. Oxid Med Cell Longev. 2019;2019:1253289. doi: 10.1155/2019/1253289. DOI: https://doi.org/10.1155/2019/1253289
  70. Carey A, Parodi-Rullan R, Vazquez-Torres R, et al. Homocysteine potentiates amyloid β -induced death receptor 4- and 5-mediated cerebral endothelial cell apoptosis, blood brain barrier dysfunction and angiogenic impairment. Aging Cell. 2024;23(5):e14106. doi: 10.1111/acel.14106. DOI: https://doi.org/10.1111/acel.14106
  71. Jakubowski H, Witucki Ł. Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int J Mol Sci. 2025;26(2):746. doi: 10.3390/ijms26020746. DOI: https://doi.org/10.3390/ijms26020746
  72. Koiso H, Tsukamoto N, Shimano S, et al. Chronic myelogenous leukemia accompanied by megaloblastic anemia showing atypical clinical features. Rinsho Ketsueki. 2011;52(11):1772–6.
  73. Arendt JF, Nexo E. Cobalamin related parameters and disease patterns in patients with increased serum cobalamin levels. PLoS One. 2012;7(9):e45979. doi: 10.1371/journal.pone.0045979. DOI: https://doi.org/10.1371/journal.pone.0045979
  74. Подзолков В.И., Драгомирецкая Н.А., Дамбаева О.Ц. и др. Гипервитаминоз В12 — новый маркер и предиктор прогностически неблагоприятных заболеваний. Терапевтический архив. 2019;91(8):160–7. doi: 10.26442/00403660.2019.08.000378. [Podzolkov V.I., Dragomiretskaya N.A., Dambaeva O.T., et al. Hypervitaminosis B12 — a new marker and predictor of prognostically unfavorable diseases. Terapevticheskii arkhiv. 2019;91(8):160–7. doi: 10.26442/00403660.2019.08.000378. (In Russ)] DOI: https://doi.org/10.26442/00403660.2019.08.000378
  75. Fadul A, Abdalla E, Mohamed A, et al. Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker. J Blood Med. 2024;15:549–56. doi: 10.2147/JBM.S474393. DOI: https://doi.org/10.2147/JBM.S474393
  76. Callaghan FM, Leishear K, Abhyankar S, et al. High vitamin B12 levels are not associated with increased mortality risk for ICU patients after adjusting for liver function: a cohort study. ESPEN J. 2014;9(2):e76–e83. doi: 10.1016/j.clnme.2014.01.003. DOI: https://doi.org/10.1016/j.clnme.2014.01.003
  77. Fedosov SN, Nexo E. Macro-B12 and Unexpectedly High Levels of Plasma B12: A Critical Review. Nutrients. 2024;16(5):648. doi: 10.3390/nu16050648. DOI: https://doi.org/10.3390/nu16050648
  78. Arendt JF, Pedersen L, Nexo E, Sørensen HT. Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study. J Natl Cancer Inst. 2013;105(23):1799–805. doi: 10.1093/jnci/djt315. DOI: https://doi.org/10.1093/jnci/djt315
  79. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta. 2002;322(1–2):21–8. doi: 10.1016/s0009-8981(02)00174-2. DOI: https://doi.org/10.1016/S0009-8981(02)00174-2
  80. Sun CF, Haven TR, Wu TL, et al. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta. 2002;321(1–2):55–62. doi: 10.1016/s0009-8981(02)00092-x. DOI: https://doi.org/10.1016/S0009-8981(02)00092-X
  81. Ефремова О.В., Мамаев А.Н., Елыкомов В.А. и др. Геморрагические нарушения и их коррекция у больных хроническим миелолейкозом на фоне терапии ингибиторами BCR-ABL-зависимой тирозинкиназы. Наука, техника и образование. 2015;2(8):116–20. [Efremova O.V., Mamaev A.N., Elykomov V.A., et al. Hemorrhagic disorders and their correction in patients with chronic myeloid leukemia on therapy with BCR-ABL-tyrosine kinase inhibitors. Nauka, tekhnika i obrazovanie. 2015;2(8):116–20. (In Russ)]
  82. Исаева Н.В., Шнякин П.Г., Алексеевич Г.Ю. и др. Ишемический инсульт в молодом возрасте на фоне хронического миелолейкоза. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2021;121(8–2):47–52. doi: 10.17116/jnevro202112108247. [Isaeva N.V., Shnyakin P.G., Alekseevich G.Yu., et al. Ischemic stroke at a young age on the context of chronic myeloleukosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8–2):47–52. doi: 10.17116/jnevro202112108247. (In Russ)] DOI: https://doi.org/10.17116/jnevro202112108247
  83. Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300–10. doi: 10.3109/10428194.2015.1091929. DOI: https://doi.org/10.3109/10428194.2015.1091929
  84. Yoshifuji K, Sasaki K. Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. Front Oncol. 2022;12:1021662. doi: 10.3389/fonc.2022.1021662. DOI: https://doi.org/10.3389/fonc.2022.1021662
  85. Choeyprasert W, Yansomdet T, Natesirinilkul R, et al. Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr Int. 2017;59(3):286–92. doi: 10.1111/ped.13136. DOI: https://doi.org/10.1111/ped.13136
  86. Omran MM, Shouman SA, Abdelfattah R, et al. Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters. Curr Ther Res Clin Exp. 2022;97:100684. doi: 10.1016/j.curtheres.2022.100684. DOI: https://doi.org/10.1016/j.curtheres.2022.100684
  87. Moura MS, Benevides TCL, Delamain MT, et al. Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. Hematol Transfus Cell Ther. 2019;41(4):329–34. doi: 10.1016/j.htct.2019.03.006. DOI: https://doi.org/10.1016/j.htct.2019.03.006
  88. Alshehry NF, Kortan P, Lipton JH. Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia. Clin Case Rep. 2014;2(3):77–8. doi: 10.1002/ccr3.49. DOI: https://doi.org/10.1002/ccr3.49
  89. El Jurdi N, Bankoff M, Klein A, Saif MW. Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML). Cureus. 2016;8(6):e660. doi: 10.7759/cureus.660. DOI: https://doi.org/10.7759/cureus.660
  90. Soylu Ustkoyuncu P, Kendirci M, Kardas F, et al. Neutropenia and Increased Mean Corpuscular Volume (MCV) With Abnormal Neurologic Findings: A Case of Cobalamin D Deficiency. J Pediatr Hematol Oncol. 2019;41(1):e54–e56. doi: 10.1097/MPH.0000000000001120. DOI: https://doi.org/10.1097/MPH.0000000000001120
  91. Jayte M, Hersi AM, Jama YM, et al. Severe Vitamin B12 deficiency with complications in an elderly patient: a case study of pancytopenia and haemolysis. Br J Community Nurs. 2025;30(4):180–3. doi: 10.12968/bjcn.2024.0132. DOI: https://doi.org/10.12968/bjcn.2024.0132
  92. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333–40. doi: 10.1200/JCO.2015.64.8899. DOI: https://doi.org/10.1200/JCO.2015.64.8899
  93. Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. doi: 10.1038/s41375-022-01589-y. DOI: https://doi.org/10.1038/s41375-022-01589-y
  94. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404. doi: 10.1182/blood-2016-09-739086. DOI: https://doi.org/10.1182/blood-2016-09-739086
  95. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–41. doi: 10.1182/blood.2020009984. DOI: https://doi.org/10.1182/blood.2020009984
  96. Haguet H, Douxfils J, Chatelain C, et al. BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? TH Open. 2018;2(1):e68–e88. doi: 10.1055/s-0038-1624566. DOI: https://doi.org/10.1055/s-0038-1624566
  97. Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol. 2020;316:214–21. doi: 10.1016/j.ijcard.2020.05.077. DOI: https://doi.org/10.1016/j.ijcard.2020.05.077
  98. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99(7):1197–203. doi: 10.3324/haematol.2014.104075. DOI: https://doi.org/10.3324/haematol.2014.104075
  99. Zeynelgil E, Sağlam B, Asıl M, Doğan Ö. Assessment Of Serum Cyanocobalamin Level And Importance In Patients with Hematological Malignancies. Turk J Clin Lab. 2023;14(2):270–3. doi: 10.18663/tjcl.1225685 DOI: https://doi.org/10.18663/tjcl.1225685
  100. Ünlü A, Ünver Koluman B, Hacıoğlu S, et al. Predictive value of serum vitamin B12 elevation in acute leukemia. Pam Med J. 2023;16(2):230–6. doi: 10.31362/patd.1210492. DOI: https://doi.org/10.31362/patd.1210492
  101. Wang D, Yang H, Zhang Y, et al. Inhibition of cystathionine β-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia. Signal Transduct Target Ther. 2021;6(1):52. doi: 10.1038/s41392-020-00410-5. DOI: https://doi.org/10.1038/s41392-020-00410-5
  102. Myszkowska J, Klotz K, Leandro P, et al. Real-time detection of enzymatically formed hydrogen sulfide by pathogenic variants of cystathionine beta-synthase using hemoglobin I of Lucina pectinata as a biosensor. Free Radic Biol Med. 2024;223:281–95. doi: 10.1016/j.freeradbiomed.2024.07.031. DOI: https://doi.org/10.1016/j.freeradbiomed.2024.07.031

Keywords:

chronic myeloid leukemia, tyrosine kinase inhibitors, homocysteine, vitamin В12

License

Copyright (c) 2026 Clinical Oncohematology. Basic Research and Clinical Practice

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Yuliana Yurevna Assesorova, PhD in Biology, Republican Specialized Scientific and Practical Medical Center of Hematology, 17 Arnasai ul., Chilanzarskii Region, Tashkent, Republic of Uzbekistan, 100115, e-mail: yuliana-as@mail.ru
2026-2

Downloads

Published

01.04.2026

Issue

Vol. 19 No. 2 (2026)
MYELOID TUMORS

How to Cite

Samarina K.S., Assesorova Y.Y., Berger I.V. Level and Serum Metabolism of Homocysteine in Chronic Myeloid Leukemia Patients: A Literature Review. Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(2):162–171. doi:10.21320/2500-2139-2026-19-2-162-171.